12:00 AM
Apr 01, 2013
 |  BC Week In Review  |  Company News  |  Deals

Edison, Dainippon Sumitomo deal

Edison granted Dainippon exclusive rights to develop and commercialize EPI-743 and EPI-589 in Japan. Edison, which retains rights to the compounds outside of Japan, will receive $35 million up front and $15 million in R&D support from...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >